Real-time Estimate
Cboe BZX
03:45:23 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
24.86
USD
|
-4.25%
|
|
-5.54%
|
-18.92%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
717.1
|
3,514
|
8,799
|
2,974
|
2,731
|
2,505
|
-
|
-
|
Enterprise Value (EV)
1 |
659.9
|
2,917
|
7,713
|
1,712
|
1,718
|
1,939
|
1,996
|
2,093
|
P/E ratio
|
-6.95
x
|
-22.7
x
|
-31.3
x
|
-5.66
x
|
-5.63
x
|
-5.04
x
|
-4.87
x
|
-4.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.6
x
|
60.6
x
|
266
x
|
57.1
x
|
75.3
x
|
36.6
x
|
42.4
x
|
21.6
x
|
EV / Revenue
|
15.3
x
|
50.3
x
|
233
x
|
32.8
x
|
47.4
x
|
28.3
x
|
33.8
x
|
18
x
|
EV / EBITDA
|
-6.55
x
|
-22.4
x
|
-29.6
x
|
-3.8
x
|
-3.39
x
|
-4.05
x
|
-3.62
x
|
-3.78
x
|
EV / FCF
|
-5.99
x
|
-54.5
x
|
-32.4
x
|
-4.94
x
|
-4.21
x
|
-5.19
x
|
-5.26
x
|
-6.05
x
|
FCF Yield
|
-16.7%
|
-1.83%
|
-3.08%
|
-20.3%
|
-23.7%
|
-19.3%
|
-19%
|
-16.5%
|
Price to Book
|
2.73
x
|
5.78
x
|
8.06
x
|
2.46
x
|
2.7
x
|
3.21
x
|
3.09
x
|
3.6
x
|
Nbr of stocks (in thousands)
|
48,882
|
64,594
|
74,419
|
85,234
|
89,555
|
96,475
|
-
|
-
|
Reference price
2 |
14.67
|
54.40
|
118.2
|
34.89
|
30.49
|
25.97
|
25.97
|
25.97
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
43.1
|
57.99
|
33.05
|
52.12
|
36.28
|
68.47
|
59.1
|
116.1
|
EBITDA
1 |
-100.8
|
-130.3
|
-261
|
-450.6
|
-506.3
|
-478.7
|
-551.5
|
-553.4
|
EBIT
1 |
-106.4
|
-136.6
|
-267.8
|
-458.2
|
-515.3
|
-508.2
|
-560.7
|
-572.1
|
Operating Margin
|
-246.78%
|
-235.51%
|
-810.37%
|
-879.04%
|
-1,420.51%
|
-742.29%
|
-948.76%
|
-492.93%
|
Earnings before Tax (EBT)
1 |
-99.53
|
-134.2
|
-267.9
|
-474.2
|
-481.2
|
-499.2
|
-539.2
|
-594.1
|
Net income
1 |
-99.53
|
-134.2
|
-267.9
|
-474.2
|
-481.2
|
-489.6
|
-532.8
|
-557
|
Net margin
|
-230.92%
|
-231.46%
|
-810.49%
|
-909.78%
|
-1,326.51%
|
-715.06%
|
-901.62%
|
-479.89%
|
EPS
2 |
-2.110
|
-2.400
|
-3.780
|
-6.160
|
-5.420
|
-5.153
|
-5.330
|
-5.417
|
Free Cash Flow
1 |
-110.2
|
-53.5
|
-237.8
|
-346.8
|
-408.1
|
-373.8
|
-379.3
|
-346.1
|
FCF margin
|
-255.7%
|
-92.25%
|
-719.41%
|
-665.46%
|
-1,124.94%
|
-545.9%
|
-641.9%
|
-298.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
12.58
|
11.25
|
14.03
|
13.27
|
13.57
|
12.61
|
13.59
|
11.99
|
-1.917
|
28.94
|
18.49
|
10.56
|
10.76
|
14.72
|
19.72
|
EBITDA
|
-
|
-
|
-
|
-103.6
|
-108.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-80.42
|
-144.2
|
-98.3
|
-105.5
|
-110.1
|
-112
|
-132.3
|
-131.1
|
-139.9
|
-114
|
-128.1
|
-140
|
-142.8
|
-144.9
|
-147.2
|
Operating Margin
|
-639.03%
|
-1,281.96%
|
-700.65%
|
-795.49%
|
-811.07%
|
-888.13%
|
-973.47%
|
-1,093.29%
|
7,297.44%
|
-394%
|
-692.8%
|
-1,324.81%
|
-1,327.24%
|
-984.12%
|
-746.45%
|
Earnings before Tax (EBT)
1 |
-81.24
|
-146.9
|
-100.7
|
-113.2
|
-113.4
|
-103.1
|
-123.7
|
-122.2
|
-132.2
|
-107.4
|
-123.4
|
-133.9
|
-137.8
|
-139.9
|
-141.7
|
Net income
1 |
-81.24
|
-146.9
|
-100.7
|
-113.2
|
-113.4
|
-103.1
|
-123.7
|
-122.2
|
-132.2
|
-107.4
|
-119.8
|
-131
|
-134
|
-139.9
|
-141.7
|
Net margin
|
-645.56%
|
-1,305.3%
|
-717.59%
|
-853.53%
|
-835.53%
|
-818.07%
|
-909.82%
|
-1,019.21%
|
6,894.16%
|
-371.3%
|
-647.81%
|
-1,240.33%
|
-1,244.98%
|
-950.38%
|
-718.39%
|
EPS
2 |
-1.090
|
-1.960
|
-1.330
|
-1.490
|
-1.380
|
-1.170
|
-1.400
|
-1.380
|
-1.460
|
-1.120
|
-1.217
|
-1.340
|
-1.358
|
-1.330
|
-1.274
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/9/23
|
2/22/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
57.2
|
597
|
1,086
|
1,262
|
1,012
|
567
|
509
|
412
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-110
|
-53.5
|
-238
|
-347
|
-408
|
-374
|
-379
|
-346
|
ROE (net income / shareholders' equity)
|
-36.3%
|
-33.7%
|
-
|
-41.7%
|
-42.1%
|
-68.1%
|
-78.6%
|
-137%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-33.7%
|
-34.1%
|
-57.2%
|
-115%
|
-153%
|
Assets
1 |
-
|
-
|
-
|
1,407
|
1,411
|
856.5
|
464.3
|
364.3
|
Book Value Per Share
2 |
5.380
|
9.410
|
14.70
|
14.20
|
11.30
|
8.090
|
8.410
|
7.210
|
Cash Flow per Share
2 |
-
|
-0.8900
|
-
|
-4.330
|
-4.440
|
-4.370
|
-2.540
|
1.780
|
Capex
1 |
6.79
|
3.59
|
12.8
|
13.6
|
14
|
11.7
|
10.9
|
10.1
|
Capex / Sales
|
15.76%
|
6.18%
|
38.59%
|
26.01%
|
38.55%
|
17.08%
|
18.42%
|
8.73%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
25.97
USD Average target price
70.26
USD Spread / Average Target +170.54% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.79% | 2.51B | | +65.40% | 62.59B | | -1.09% | 41.18B | | +44.76% | 40.29B | | -8.29% | 27.9B | | +13.10% | 26.21B | | -21.56% | 19.09B | | +5.27% | 13.08B | | +25.31% | 12.26B | | +28.25% | 12.05B |
Other Biotechnology & Medical Research
|